Impact biomedical, inc. announces u.s. patent allowance of laetose™ technology entitled "low glycemic sugar composition."

New york, jan. 30, 2024 (globe newswire) -- impact biomedical inc. (ibio), in which dss inc.(nyse american: dss) has a significant investment, is thrilled to announce a milestone in its innovative laetose™ technology platform. the u.s. patent and trademark office (uspto) has issued u.s. patent # 11,898,184, entitled "low glycemic sugar composition" developed within this platform.
DSS Ratings Summary
DSS Quant Ranking